Tocqueville Asset Management L.P. Makes New $913,000 Investment in Immix Biopharma, Inc. $IMMX

Tocqueville Asset Management L.P. bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX) during the 2nd quarter, Holdings Channel reports. The firm bought 88,550 shares of the company’s stock, valued at approximately $913,000.

Other hedge funds have also recently modified their holdings of the company. Janus Henderson Group PLC acquired a new position in Immix Biopharma in the 4th quarter valued at $20,471,000. BlackRock Inc. purchased a new stake in shares of Immix Biopharma in the second quarter valued at about $30,827,000. Eventide Asset Management LLC acquired a new position in shares of Immix Biopharma during the fourth quarter worth about $13,331,000. Marshall Wace LLP raised its holdings in Immix Biopharma by 3,495.4% during the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock worth $10,349,000 after purchasing an additional 1,923,708 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Immix Biopharma in the fourth quarter valued at about $8,681,000. 11.26% of the stock is owned by institutional investors and hedge funds.

Immix Biopharma Stock Performance

IMMX stock opened at $13.16 on Friday. The stock’s 50 day moving average price is $9.98 and its 200 day moving average price is $9.24. The firm has a market cap of $941.47 million, a P/E ratio of -14.95 and a beta of 0.11. Immix Biopharma, Inc. has a 1 year low of $1.94 and a 1 year high of $13.20.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, research analysts predict that Immix Biopharma, Inc. will post -0.74 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a research report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a report on Friday, July 17th. HC Wainwright upped their price target on shares of Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Bank of America initiated coverage on shares of Immix Biopharma in a report on Thursday, June 18th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, Lifesci Capital initiated coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 target price for the company. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Immix Biopharma has an average rating of “Moderate Buy” and an average price target of $21.29.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.